CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer

Su-Jung Kim, Soyeon Kim, Dong-Wan Kim, Miso Kim, Bhumsuk Keam, Tae Min Kim, Yusoo Lee, Jaemoon Koh, Yoon Kyung Jeon, Dae Seog Heo

Cancer Research and Treatment. 2019;51(3):1231-1240. Published online 2018 December 31 DOI: https://doi.org/10.4143/crt.2018.486

Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer

Su-Jung Kim, Soyeon Kim, Dong-Wan Kim, Miso Kim, Bhumsuk Keam, Tae Min Kim, Yusoo Lee, Jaemoon Koh, Yoon Kyung Jeon, Dae Seog Heo

Cancer Research and Treatment. 2019;51(3):1231-1240

Link1

Link2 Link3

ALK fusion variant 3a/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061)

Meichen Li, Xue Hou, Jing Chen, Baishen Zhang, Na Wang, Hongyu Han, Likun Chen

Lung Cancer. 2022;165:54-62

Link1 Link2

Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors

Delphine Levacq, Nicky D’Haene, Roland de Wind, Myriam Remmelink, Thierry Berghmans

Lung Cancer. 2016;102:38-41

Link1 Link2

ALK rearranged lung cancer: TKI treatment and outcome

Ana Collazo-Lorduy, Beatriz Jiménez, María Castro-Henriques, Jordi Remon

Therapeutic Strategies to Overcome ALK Resistance in Cancer. 2021;31-53

Link1 Link2

Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis

Daniel Breadner, Phillip Blanchette, Sumugan Shanmuganathan, Ronald Gabriel Boldt, Jacques Raphael

Lung Cancer. 2020;144:57-63

Link1 Link2

Strong ALK and PD-L1 positive IHC expression related ALK amplification in an advanced lung sarcomatoid carcinoma: A therapeutic trap?

Sébastien Gendarme, Lise Matton, Martine Antoine, Khaldoun Kerrou, Anne-Marie Ruppert, Christelle Epaud, Jacques Cadranel, Vincent Fallet

Lung Cancer. 2021;152:94-97

Link1 Link2

Identification of a novel resistance ALK p.(Q1188_L1190del) deletion in a patient with ALK-rearranged non–small-cell lung cancer

Moushumi Suryavanshi, Krushna Chaudhari, Shrinidhi Nathany, Vineet Talwar

Cancer Genetics. 2021;256-257:48-50

Link1 Link2

A patient previously treated with ALK inhibitors for central nervous system lesions from ALK rearranged lung cancer: a case report

Jumpei Kashima, Yusuke Okuma, Tsunekazu Hishima

OncoTargets and Therapy. 2016;Volume 9:6059-6063

Link1 Link2

Overcoming crizotinib resistance in ALK-rearranged non-small cell lung cancer

Xiaolong Qi, Wang Ma, Sen Li, Caicun Zhou

Lung Cancer. 2014;85(2):335-336

Link1 Link2

P1.07-042 PD-L1 and CD8 Expression in EGFR-Mutant or ALK-Rearranged Patients with Lung Cancer

S. Liu, Z. Dong, S. Wu, Z. Xie, J. Su, J.-. Yang, X. Yang, Y. Wu

Journal of Thoracic Oncology. 2017;12(11):S2012-S2013

Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.